Key Points
- CEO Michael Myers purchased 20,490 QNRX shares at an average price of $4.88, investing nearly $100,000 and increasing his stake by 118.97% to 37,713 shares.
- Quoin Pharmaceuticals shares were trading at $6.51, up 4.7%, but the company reported a quarterly EPS loss of $1.90, missing analyst expectations of a $1.61 loss.
- Analyst sentiment is mixed, with one Buy and one Sell rating resulting in a consensus “Hold”; institutional investors own 8.63% of the company.
Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX - Get Free Report) Director Anthony James Culverwell purchased 6,146 shares of Quoin Pharmaceuticals stock in a transaction dated Monday, August 31st. The stock was acquired at an average price of $4.88 per share, for a total transaction of $29,992.48. Following the completion of the acquisition, the director owned 40,364 shares of the company's stock, valued at approximately $196,976.32. This trade represents a 17.96% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Quoin Pharmaceuticals Stock Up 4.7%
QNRX opened at $6.51 on Wednesday. The business has a fifty day moving average of $4.77 and a 200 day moving average of $5.89. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a 52-week low of $3.25 and a 52-week high of $41.80. The stock has a market cap of $13.09 million, a P/E ratio of -0.26 and a beta of 1.50.
Quoin Pharmaceuticals (NASDAQ:QNRX - Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($1.90) earnings per share for the quarter, missing analysts' consensus estimates of ($1.61) by ($0.29). Equities analysts anticipate that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.38 EPS for the current fiscal year.
Hedge Funds Weigh In On Quoin Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in QNRX. Simplify Asset Management Inc. bought a new stake in shares of Quoin Pharmaceuticals in the fourth quarter valued at about $252,000. ADAR1 Capital Management LLC bought a new position in Quoin Pharmaceuticals during the 4th quarter worth about $840,000. Boothbay Fund Management LLC bought a new position in Quoin Pharmaceuticals during the 4th quarter worth about $863,000. SummitTX Capital L.P. purchased a new position in Quoin Pharmaceuticals during the 4th quarter valued at about $935,000. Finally, Millennium Management LLC purchased a new position in Quoin Pharmaceuticals during the 4th quarter valued at about $1,080,000. Institutional investors own 8.63% of the company's stock.
Wall Street Analysts Forecast Growth
QNRX has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Quoin Pharmaceuticals in a research note on Monday, July 20th. ThinkEquity started coverage on shares of Quoin Pharmaceuticals in a research note on Monday, June 15th. They issued a "buy" rating on the stock. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold".
View Our Latest Stock Analysis on QNRX
Quoin Pharmaceuticals Company Profile
(
Get Free Report)
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
